Quadalti Corinne, Moretti Marzia, Ferrazzi Fabio, Calzà Laura, Giardino Luciana, Baldassarro Vito Antonio
Department of Pharmacy and Biotechnology (FaBiT), University of Bologna, Bologna, Italy.
Interdepartmental Centre for Industrial Research in Health Sciences and Technology ICIR-HST, University of Bologna, Bologna, Italy.
Front Toxicol. 2025 May 8;7:1561386. doi: 10.3389/ftox.2025.1561386. eCollection 2025.
The international guidelines outlining the mandatory developmental toxicology studies of new molecules on pre-implantation, post-implantation and organogenesis phases, require a minimum of 60 pregnant female rats for each molecule to be tested. To date, available in vitro methods still have many limitations, resulting in poor translational power.
In the present study, an innovative in vitro platform is proposed, based on rat embryonic stem cells (RESCs), which is easy to use and suitable for wide-scale screening, mimicking two different developmental stages: i) pre-implant model (undifferentiated pluripotent cells), ii) post-implant model (neuroectodermal lineage differentiation).
The in vitro platform was validated by testing the toxicity on the pre-implant model of RA itself, as a known teratogen, a member of the environmental pollutant family per- and polyfluoroalkyl substances (PFAS), the perfluorooctanic acid (PFOA), and the endocrine disruptor chemical 2,2',6,6'-tetrabromobisphenol A (TBBPA) as test compound, targeting the thyroid hormone (TH) signal. The post-implant model showed inactivation of the pluripotent markers and activation of the neuroectodermal markers. The preimplant model resulted high responsive and sensitive to the embryotoxic effect of the tested compounds. The TBBPA was selected to test the potential effects of on viability and neuroectodermal differentiation, assessed through colorimetric and cell-based high-content screening methods establishing sub-toxic (20 μM) and toxic (40 μM) doses. A high-throughput gene expression array-based analysis showed a prompt response of the in vitro testing platform to TBBPA treatment. A rescue experiment exploiting a pan-thyroid receptor (pan-TR) inhibitor (1-850) showed that the effects of TBBPA on RESCs was blocked, demonstrating its activity through TRs.
The RESCs-based platform allowed reproducible, robust and highly predictable results, thanks to the coupling of RESCs with high-throughput technologies. These results support the possible use of RESCs-based models as a screening platform for developmental toxicity testing to reduce the number of animals currently used for this aim.
国际指南概述了新分子在植入前、植入后和器官发生阶段的强制性发育毒理学研究,要求对每种待测试分子至少使用60只怀孕的雌性大鼠。迄今为止,现有的体外方法仍有许多局限性,导致转化能力较差。
在本研究中,提出了一种基于大鼠胚胎干细胞(RESCs)的创新体外平台,该平台易于使用且适用于大规模筛选,模拟两个不同的发育阶段:i)植入前模型(未分化的多能细胞),ii)植入后模型(神经外胚层谱系分化)。
通过测试视黄酸(RA)本身(一种已知的致畸剂,属于环境污染物全氟和多氟烷基物质(PFAS)家族的成员)、全氟辛酸(PFOA)以及内分泌干扰化学物质2,2',6,6'-四溴双酚A(TBBPA)在植入前模型上的毒性来验证该体外平台,这些物质作为测试化合物,靶向甲状腺激素(TH)信号。植入后模型显示多能性标志物失活,神经外胚层标志物激活。植入前模型对测试化合物的胚胎毒性作用反应高度灵敏。选择TBBPA通过比色法和基于细胞的高内涵筛选方法测试其对活力和神经外胚层分化的潜在影响,确定亚毒性(20 μM)和毒性(40 μM)剂量。基于高通量基因表达阵列的分析表明体外测试平台对TBBPA处理有快速反应。利用泛甲状腺受体(pan-TR)抑制剂(1-850)进行的挽救实验表明,TBBPA对RESCs的作用被阻断,证明其通过TRs发挥活性。
基于RESCs的平台由于将RESCs与高通量技术相结合,能够产生可重复、可靠且高度可预测的结果。这些结果支持将基于RESCs的模型用作发育毒性测试的筛选平台,以减少目前用于该目的的动物数量。